Odyssey Therapeutics (ODTX) Competitors

$19.36 +0.22 (+1.15%)
As of 04:00 PM Eastern

ODTX vs. AMLX, ABCL, IRON, LEGN, and ELVN

Should you buy Odyssey Therapeutics stock or one of its competitors? Odyssey Therapeutics's main competitors and comparable companies include Amylyx Pharmaceuticals (AMLX), AbCellera Biologics (ABCL), Disc Medicine (IRON), Legend Biotech (LEGN), and Enliven Therapeutics (ELVN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Odyssey Therapeutics compare to Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Odyssey Therapeutics (NASDAQ:ODTX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Amylyx Pharmaceuticals currently has a consensus price target of $43.71, suggesting a potential upside of 44.32%. Odyssey Therapeutics has a consensus price target of $34.67, suggesting a potential upside of 81.12%. Given Odyssey Therapeutics' higher probable upside, analysts plainly believe Odyssey Therapeutics is more favorable than Amylyx Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amylyx Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.00
Odyssey Therapeutics
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80

Odyssey Therapeutics has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amylyx Pharmaceuticals$87.37M44.57-$144.74M-$1.44N/A
Odyssey TherapeuticsN/AN/AN/A-$9.13N/A

Odyssey Therapeutics' return on equity of 0.00% beat Amylyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Amylyx PharmaceuticalsN/A -41.54% -38.91%
Odyssey Therapeutics N/A N/A N/A

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Amylyx Pharmaceuticals had 1 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 11 mentions for Amylyx Pharmaceuticals and 10 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.04 beat Amylyx Pharmaceuticals' score of 0.50 indicating that Odyssey Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amylyx Pharmaceuticals
1 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Odyssey Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Amylyx Pharmaceuticals beats Odyssey Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Odyssey Therapeutics compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and Odyssey Therapeutics (NASDAQ:ODTX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

Odyssey Therapeutics has lower revenue, but higher earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbCellera Biologics$67.85M55.31-$146.41M-$0.48N/A
Odyssey TherapeuticsN/AN/AN/A-$9.13N/A

Odyssey Therapeutics has a net margin of 0.00% compared to AbCellera Biologics' net margin of -218.54%. Odyssey Therapeutics' return on equity of 0.00% beat AbCellera Biologics' return on equity.

Company Net Margins Return on Equity Return on Assets
AbCellera Biologics-218.54% -15.35% -10.84%
Odyssey Therapeutics N/A N/A N/A

AbCellera Biologics presently has a consensus target price of $16.20, suggesting a potential upside of 40.99%. Odyssey Therapeutics has a consensus target price of $34.67, suggesting a potential upside of 81.12%. Given Odyssey Therapeutics' higher possible upside, analysts clearly believe Odyssey Therapeutics is more favorable than AbCellera Biologics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AbCellera Biologics
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
2.91
Odyssey Therapeutics
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80

In the previous week, AbCellera Biologics had 14 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 24 mentions for AbCellera Biologics and 10 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.04 beat AbCellera Biologics' score of 0.53 indicating that Odyssey Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AbCellera Biologics
4 Very Positive mention(s)
4 Positive mention(s)
10 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Odyssey Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

61.4% of AbCellera Biologics shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

AbCellera Biologics beats Odyssey Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Odyssey Therapeutics compare to Disc Medicine?

Odyssey Therapeutics (NASDAQ:ODTX) and Disc Medicine (NASDAQ:IRON) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Odyssey Therapeutics presently has a consensus price target of $34.67, suggesting a potential upside of 81.12%. Disc Medicine has a consensus price target of $124.18, suggesting a potential upside of 55.23%. Given Odyssey Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Odyssey Therapeutics is more favorable than Disc Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Odyssey Therapeutics
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80
Disc Medicine
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.79

Odyssey Therapeutics' return on equity of 0.00% beat Disc Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Odyssey TherapeuticsN/A N/A N/A
Disc Medicine N/A -36.33%-32.50%

In the previous week, Disc Medicine had 9 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 19 mentions for Disc Medicine and 10 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.04 beat Disc Medicine's score of 0.74 indicating that Odyssey Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Odyssey Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Disc Medicine
5 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Disc Medicine is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Odyssey TherapeuticsN/AN/AN/A-$9.13N/A
Disc MedicineN/AN/A-$212.18M-$6.34N/A

83.7% of Disc Medicine shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Odyssey Therapeutics beats Disc Medicine on 7 of the 12 factors compared between the two stocks.

How does Odyssey Therapeutics compare to Legend Biotech?

Odyssey Therapeutics (NASDAQ:ODTX) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

Odyssey Therapeutics has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Odyssey TherapeuticsN/AN/AN/A-$9.13N/A
Legend Biotech$1.03B3.30-$296.80M-$0.01N/A

Odyssey Therapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -0.02%. Odyssey Therapeutics' return on equity of 0.00% beat Legend Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Odyssey TherapeuticsN/A N/A N/A
Legend Biotech -0.02%-0.03%-0.02%

In the previous week, Legend Biotech had 27 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 37 mentions for Legend Biotech and 10 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.04 beat Legend Biotech's score of -0.14 indicating that Odyssey Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Odyssey Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Legend Biotech
2 Very Positive mention(s)
5 Positive mention(s)
13 Neutral mention(s)
8 Negative mention(s)
2 Very Negative mention(s)
Neutral

Odyssey Therapeutics presently has a consensus target price of $34.67, suggesting a potential upside of 81.12%. Legend Biotech has a consensus target price of $50.85, suggesting a potential upside of 190.55%. Given Legend Biotech's higher probable upside, analysts clearly believe Legend Biotech is more favorable than Odyssey Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Odyssey Therapeutics
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80
Legend Biotech
1 Sell rating(s)
6 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.50

70.9% of Legend Biotech shares are held by institutional investors. 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Odyssey Therapeutics and Legend Biotech tied by winning 7 of the 14 factors compared between the two stocks.

How does Odyssey Therapeutics compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Odyssey Therapeutics (NASDAQ:ODTX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Enliven Therapeutics currently has a consensus price target of $75.44, indicating a potential upside of 54.60%. Odyssey Therapeutics has a consensus price target of $34.67, indicating a potential upside of 81.12%. Given Odyssey Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Odyssey Therapeutics is more favorable than Enliven Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enliven Therapeutics
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75
Odyssey Therapeutics
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80

Odyssey Therapeutics' return on equity of 0.00% beat Enliven Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Enliven TherapeuticsN/A -16.91% -16.52%
Odyssey Therapeutics N/A N/A N/A

In the previous week, Odyssey Therapeutics had 2 more articles in the media than Enliven Therapeutics. MarketBeat recorded 10 mentions for Odyssey Therapeutics and 8 mentions for Enliven Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.04 beat Enliven Therapeutics' score of 0.98 indicating that Odyssey Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Enliven Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Odyssey Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

95.1% of Enliven Therapeutics shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enliven TherapeuticsN/AN/A-$103.69M-$1.71N/A
Odyssey TherapeuticsN/AN/AN/A-$9.13N/A

Summary

Odyssey Therapeutics beats Enliven Therapeutics on 8 of the 12 factors compared between the two stocks.

Get Odyssey Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ODTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ODTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ODTX vs. The Competition

MetricOdyssey TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$966.16M$4.15B$7.85B$12.17B
Dividend YieldN/A3.62%2.46%4.41%
P/E RatioN/A26.5532.9127.39
Price / SalesN/A16.028.595.74
Price / CashN/A26.3721.9322.50
Price / Book2.484.074.403.70
Net IncomeN/A-$22.86M$3.52B$392.17M
7 Day Performance1.10%-7.26%-5.34%-4.53%
1 Month Performance12.75%-4.96%-3.61%-5.86%
1 Year PerformanceN/A-2.87%0.01%-7.78%

Odyssey Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ODTX
Odyssey Therapeutics
2.5848 of 5 stars
$19.36
+1.1%
$34.67
+79.1%
N/A$966.16MN/AN/A100
AMLX
Amylyx Pharmaceuticals
3.0281 of 5 stars
$30.29
+1.4%
$43.71
+44.3%
+138.7%$3.84B$87.37MN/A136
ABCL
AbCellera Biologics
3.9259 of 5 stars
$11.49
-1.1%
$16.20
+41.0%
+211.4%$3.80B$75.13MN/A562
IRON
Disc Medicine
3.8172 of 5 stars
$80.00
-3.9%
$124.18
+55.2%
-11.1%$3.79BN/AN/A165
LEGN
Legend Biotech
3.2132 of 5 stars
$17.50
-5.6%
$50.85
+190.5%
-42.2%$3.59B$1.03BN/A2,965

Related Companies and Tools


This page (NASDAQ:ODTX) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners